3401 On Other Exchanges
3401 is not on other exchanges.

teijin ltd (3401) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TEIJIN LTD (3401)

Related News

No related news articles were found.

teijin ltd (3401) Related Businessweek News

No Related Businessweek News Found

teijin ltd (3401) Details

Teijin Limited engages in advanced fibers and composites, electric materials and performance polymer products, healthcare, products converting, and IT businesses worldwide. The company’s Advanced Fibers and Composites segment offers para-aramid, meta-aramid, polyester, and polyethylene naphthalate (PEN) fibers; artificial leather; carbon fibers and intermediate materials; carbon fiber reinforced composites; and flame-resistant fibers. Its Electronics Materials and Performance Polymer Products segment provides polycarbonate (PC) resins, PC/ABS and PC/AS polymer alloys, PEN resins, polyethylene terephthalate (PET) resins, polybutylene naphthalete resins, flame retardants, PET and PEN films, processed films, raw materials, and polymers. The company’s Healthcare segment offers Bonalon and Onealfa for the treatment of osteoporosis; Synvisc to treat knee osteoarthritis pain; sonic accelerated fracture healing systems; Mucosolvan, an expectorant; and Alvesco, an inhaled corticosteroid agent for asthma. This segment also provides oxygen concentrators for home oxygen therapy; continuous positive airway pressure units; NIP NASAL, a non-invasive positive pressure ventilator; AutoSet CS, an adaptive servo-ventilator; Feburic to treat hyperuricemia and gout; Tricor for hyperlipidemia; and Venilon for intravenous immunoglobulin preparation. Its Trading and Retail segment engages in the trading and retail of polyester filaments, other fibers, and polymer products. The company also offers IT services in the healthcare field, Web-based enterprise resource planning software, and digital content management services; and content distribution services for mobile phones and smartphones, and e-commerce services. Teijin Limited was founded in 1918 and is headquartered in Osaka, Japan.

19,292 Employees
Last Reported Date: 06/22/17
Founded in 1918

teijin ltd (3401) Top Compensated Officers

Chief Executive Officer, President, Member of...
Total Annual Compensation: ¥104.0M
Compensation as of Fiscal Year 2017.
teijin ltd
Teijin Limited, Q1 2018 Earnings Call, Aug 01, 2017

Teijin Limited, Q1 2018 Earnings Call, Aug 01, 2017

Teijin Limited Expects Interim Dividend and Annual Dividend for the Fiscal 2017

Teijin Limited expects interim dividend of ¥30 per share and annual dividend of ¥30 per share for the fiscal 2017. No changes from previous outlook.

Teijin Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Consolidated Earnings Guidance for the First Six Months of Fiscal 2018; Revised Consolidated Earnings Guidance for the Year Ending March 31, 2018

Teijin Ltd. reported consolidated earnings results for the first quarter ended June 30, 2017. For the quarter, the company reported net sales of ¥198,239 million against ¥174,226 million a year ago. Operating income was ¥19,145 million against ¥15,697 million a year ago. Ordinary income was ¥20,039 million against ¥14,400 million a year ago. Profit attributable to owners of parent was ¥13,396 million against ¥11,436 million a year ago. Diluted E.P.S. was ¥61.68 against ¥52.74 a year ago. Capex was ¥8.8 million. Profit before income taxes was ¥19,559 million against ¥13,751 million a year ago. For the first six months, the company expects net sales of ¥415,000 million, operating income of ¥33,000 million, ordinary income of ¥34,000 million, profit attributable to owners of parent of ¥26,000 million or ¥132.15 per share. Looking at its consolidated full-term operating results forecasts for the fiscal 2018, the company has maintain its previous net sales forecast of ¥855.0 billion. Meanwhile, in line with factors such as the recording of consideration for licensing out an investigational preclinical antibody candidate, the company now expects to report operating income of ¥64.0 billion, compared with its previous forecast of ¥62.0 billion, and ordinary income of ¥65.0 billion, compared with its previous forecast of ¥63.0 billion, profit attributable to owners of parent is forecast at ¥44.0 billion, compared with its previous forecast of ¥42.0 billion. The company expects earnings per share of ¥223.64 per share and capital expenditure of ¥60 billion.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

3401 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 3401.
View Industry Companies

Industry Analysis


Industry Average

Valuation 3401 Industry Range
Price/Earnings 9.3x
Price/Sales 0.6x
Price/Book 1.2x
Price/Cash Flow 7.4x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TEIJIN LTD, please visit www.teijin.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.